A defect in the antioxidant defense system in schizophrenia

Neuropsychobiology

Volumn 60, Issue 2, 2009, Pages 87-93

  Virit, Osman ^a   Altindag, Abdurrahman ^a   Yumru, Mehmet ^b   Dalkilic, Alican ^e,f   Savas, Haluk Asuman ^a   Selek, Sahabettin ^c   Erel, Ozcan ^c   Herken, Hasan ^d  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Department of Psychiatry

^c HARRAN UNIVERSITY   (Turkey)

^d PAMUKKALE UNIVERSITY   (Turkey)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f St Elizabeths Hospital   (United States)

Author keywords

Oxidative stress index; Schizophrenia; Total antioxidant status; Total oxidant status

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOXIDANT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CELL DAMAGE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SMOKING; YOUNG ADULT;

EID: 70349261206     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000239684     Document Type: Article

References (44)

1. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine, ed 3. London, Oxford University Press, Oxford Science Publications, 2000, pp 617-624.
2. Halliwell B, Aruoma OI: DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 1991; 281: 9-19.
3. Cooke MS, Evans MD, Dizdaroglu M, Lunec J: Oxidative DNA damage: mechanisms, mutation and disease. FASEB J 2003; 17: 1195-1214. (Pubitemid 36775767)
4. Casarino DS, Bennett JP Jr: An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Rev 1999; 29: 1-25.
5. Mahadik SP, Mukherjee S: Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 1996; 19: 1-7.
6. Zoroglu SS, Herken H, Yürekli M, Uz E, Tutkun H, Sava° HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, Akyol O: The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002; 36: 309-315. (Pubitemid 34764055)
7. Li HC, Chen QZ, Ma Y, Zhou JF: Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. J Zhejiang Univ Sci B 2006; 7: 981-986.
8. Yao JK, Leonard S, Reddy RD: Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004; 30: 923-934.
9. Vaiva G, Thomas P, Leroux JM, Cottencin O, Dutoit D, Erb F, Goudemand M: Erythrocyte superoxide dismutase (eSOD) determination in positive moments of psychosis. Therapie 1994; 49: 343-348.
10. Yao JK, Reddy R, McElhinny LG, van Kammen DP: Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998; 32: 385-391.
11. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O: Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001; 6: 66-73.
12. Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A: Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 155-159.
13. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 995-1005.
14. Yao JK, Reddy RD, van Kammen DP: Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999; 45: 1512-1515.
15. Yao JK, Reddy R, van Kammen DP: Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000; 97: 137-151.
16. Reddy R, Keshavan M, Yao JK: Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003; 62: 205-212.
17. Yeum KJ, Russell RM, Krinsky NI, Aldini G: Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 2004; 430: 97-103.
18. Erel O: A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119.
19. Erel O: A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.
20. Selek S, Herken H, Bulut M, Ceylan MF, Celik H, Savas HA, Erel O: Oxidative imbalance in obsessive compulsive disorder patients: A total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 487-491.
21. Harma MI, Harma M, Erel O: Measuring plasma oxidative stress biomarkers in sport medicine. Eur J Appl Physiol 2006; 97: 505, author reply 506-508.
22. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E: Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006; 60: 458-464.
23. Sofic E, Rustembegovic A, Kroyer G, Cao G: Serum antioxidant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. J Neural Transm 2002; 109: 711-719.
24. Yao JK, Reddy R, McElhinny LG, van Kammen DP: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998; 32: 1-8. (Pubitemid 28338118)
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2000.
26. World Medical Organization: Declaration of Helsinki. Br Med J 1996; 313: 1448-1449.
27. Kay SR, Fiszbein PS, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
28. Guy W: Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338). Rockville, National Institute of Mental Health, 1976, pp 218-222.
29. Cao G, Prior RL: Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998; 44: 1309-1315.
30. Yao JK, Reddy R, van Kammen DP: Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80: 29-39. (Pubitemid 28370837)
31. Parikh V, Khan MM, Mahadik SP: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003; 37: 43-51.
32. Pillai A, Parikh V, Terry AV Jr, Mahadik SP: Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007; 41: 372-386.
33. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A: Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 2004; 49: 205-209.
34. Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM: Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003; 73: 364-368.
35. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E: Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short-term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1164-1169.
36. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, Zhou DF: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006; 81: 291-300.
37. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z: Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004; 35: 401-405.
38. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC: The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003; 23: 128-131.
39. Qing H, Xu H, Wei Z, Gibson K, Li XM: The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 2003; 17: 1563-1570.
40. Yao JK, Leonard S, Reddy RD: Altered glutathione redox state in schizophrenia. Dis Markers 2006; 22: 83-93.
41. Do KQ, Trabesinger AH, Kristen-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M: Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000; 12: 3721-3728.
42. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003; 62: 195-204.
43. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandöl E: The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1493-1499.
44. Mahadik SP, Pillai A, Joshi S, Foster A: Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006; 18: 119-131.